Denosumab Versus Zoledronic Acid for Reducing Time to Skeletal Events in Multiple Myeloma
Approximately 90 percent of patients diagnosed with multiple myeloma (MM) present with bone lesions and are typically treated with zoledronic acid (ZA), a potentially...
Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients...
bb2121: Is CAR T-Cell Therapy Moving to Myeloma?
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...
Multiple Myeloma Outcomes Differ Based on Socioeconomic Factors
Despite the gains made in improving treatment for and care of patients with multiple myeloma (MM), disparities persist based on race and socioeconomic status....
Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095
More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from the Serágnoli Institute of Hematology at Bologna University School...
BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma
In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of patients with heavily-pretreated multiple myeloma (MM) responded to treatment...
Controversies in Myeloma: The Who, When, and Why of Treatment
The recent expansion of treatment options for patients with multiple myeloma (MM) has introduced new opportunities for redefining the goals of therapy. At the...
Previous Malignancy May Increase Risk of Subsequent Malignancy in Patients With Myeloma
A number of new treatments for patients with multiple myeloma (MM) have become available in recent years, enabling patients to live longer. Unfortunately, these...
Early Phase Study of Selinexor With and Without Dexamethasone for Patients With Myeloma and...
According to results of a phase I study published in Blood, treatment with the XPO1 inhibitor selinexor and dexamethasone led to half of patients...
How I Treat in Brief: New Agents in Myeloma
This month, Philippe Moreau, MD, discusses the changing landscape of multiple myeloma (MM) therapeutics and options for treatment in frontline and relapsed settings.
This material...
Current Issue
August 2018, Volume 4, Issue 10
This issue features a look at direct-to-consumer pharmaceutical advertising, advice to graduating hematologists, and more.
